Multidrug resistance (MDR) is usually correlated with the poor prognosis of gastric cancer. In this study, we revealed a total of 11 microRNAs (miRNA) that regulated MDR of gastric cancer via high-throughput functional screening, and miR-508-5p reversed MDR most efficiently among these candidate miRNAs. The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo. Further studies showed that miR-508-5p could directly target the 3 0 -untranslated regions of ABCB1 and Zinc ribbon domain-containing 1 (ZNRD1), and suppress their expression at the mRNA and protein levels. Meanwhile, the suppression of ZNRD1 led to a decrease in ABCB1. These findings suggest that a miR-508-5p/ZNRD1/ABCB1 regulatory loop has a critical role in MDR in gastric cancer. In addition, miR-508-5p could be used as a prognostic factor for overall survival in gastric cancer. These data reveal an important role for miR-508-5p in the regulation of MDR in gastric cancer, and suggest the potential application of miR-508-5p in drug resistance prediction and treatment.
INTRODUCTION
Cancer is the second leading cause of death worldwide, and gastric cancer remains one of the most common malignancies. In spite of the decline in the incidence and mortality of gastric cancer in recent years, the 5-year survival rate of patients with gastric cancer remains relatively low. 1 Currently, surgical treatment and chemotherapy are the main strategies used to manage gastric cancer. However, certain patients who receive chemotherapy show a poor initial response or gradually develop resistance to chemotherapy. This phenomenon, known as multidrug resistance (MDR), could account for the poor improvement in the 5-year survival rate of gastric cancer patients. 1, 2 The mechanisms underlying MDR have been widely studied, but the phenomenon is not fully understood. According to our current understanding, MDR is generally caused by 'pre-target', 'ontarget' and 'post target' resistance. 3 'Pre-target' resistance refers to the adaptions that cancer cells make to increase the export and decrease the uptake of drugs. Drug transporters have key roles in 'pre-target' resistance, and P-glycoprotein (P-gp) is one of the best studied molecules in drug resistance. 4 ,5 P-gp was reported to be associated with resistance to multiple drugs in various types of cancer, and changes in its expression or function could contribute to MDR. [4] [5] [6] 'On-target' resistance represents structural or functional alterations to the actual targets of drugs, which suppress the effect of the drug. In cisplatin (CDDP)-resistant cells, for example, the increased repair of inter-and intra-strand DNA adducts prevents the accumulation of DNA damage due to CDDP and the subsequent activation of apoptosis. 3 'Post resistance' can result from a series of alterations to the components of signal transduction pathways or the key regulators in cell death execution. The abnormal expression and function of apoptosis-associated molecules, including Bax, Bcl-2 and caspases, could contribute to resistance to drug-induced apoptosis. [7] [8] [9] In addition, the inactivation of TP53 and XIAP-associated factor 1 has been reported to inhibit apoptosis. 10, 11 In addition to the classical MDR-associated proteins, our group also identified a series of MDR-associated molecules. Zinc ribbon domain-containing 1 (ZNRD1) was found to be increased in drug-resistant gastric cancer cells, and its inhibition could sensitize cells to various chemotherapeutics. 12, 13 Using an small interfering RNA (siRNA) library, we silenced GAS1 and observed the subsequent resistance to epirubicin.
14 Ribosomal protein L23 promoted MDR in gastric cancer cells through regulating drug-induced apoptosis. 15 Although a wide range of MDR-associated molecules have been found, the mechanisms underlying their functions and their interactions remain to be fully studied.
MicroRNAs (miRNAs) are a class of noncoding RNAs that are 21-25 nucleotides in length and function as regulators of gene expression. 16 By targeting the 3 0 -untranslated region (3 0 -UTR) of a specific mRNA via base pairing, miRNAs trigger either translational repression or mRNA degradation. 17 Accumulating evidence shows that miRNAs have an important role in the MDR of various cancers. [18] [19] [20] [21] [22] [23] In gastric cancer, miRNAs, including miR-27a, miR-497, miR-200c, miR-181b, miR-15b and miR-16, have been reported to be involved in MDR. [24] [25] [26] [27] [28] Those miRNAs function by targeting different genes, most of which are associated with apoptosis pathways, including BCL-2 and XIAP. Another area of interest is how miRNAs regulate drug resistance through transporters, and how these MDR-associated molecules could be connected via miRNAs. 1 In this report, we used a real-time cell electronic sensing (RT-CES) system to compare the drug responses of cells before and after transfection with individual miRNAs. The RT-CES system uses E-plates, and the impedance generated by the cells in each well is detected by the computer and calculated as a cell index (CI). The CI reflects the number of cells in each well, and increases in the spread and adhesion of cells also contribute to an increased CI. By analysing the CI changes caused by the transfection of individual miRNAs, we identified 11 miRNAs that improve drug sensitivity when overexpressed. Among those miRNAs, miR-508-5p reversed drug resistance most efficiently. We then found that the ectopic expression of miR-508-5p reversed drug resistance in gastric cancer both in vitro and in vivo, whereas the loss of miR-508-5p decreased drug sensitivity. In addition, we identified P-gp and ZNRD1 as two direct and functional targets of miR-508-5p, and characterized a regulatory loop composed of miR-508-5p and its targets. Finally, we confirmed the inverse correlation between the expression of miR-508-5p and its targets, and found that gastric cancer samples with lower miR-508-5p expression tended to be resistant to chemotherapy.
RESULTS

Identification of MDR-related miRNAs by functional screening
To identify miRNAs that regulate drug resistance in gastric cancer, 100 nM mimics of individual miRNAs were transfected into SGC7901/ vincristine (VCR) cells. The results revealed that 11 of these miRNA mimics led to a decreased CI in the presence of VCR ( Figures 1a  and b) ; of these, miR-508-5p had the lowest Z-score (Z-score ¼ À 5.95) and provoked the greatest decrease in growth rate (1.0 vs 0.29 ± 0.01, Po0.01). To exclude the possibility that the reversion of drug resistance was because of the miRNA-mediated suppression of cell proliferation, we compared the growth rates between cells in drug-free medium that were or were not transfected with miRNA mimics. The results showed that miR-15b and miR-582-5p slightly suppressed the growth of SGC7901/VCR cells (Figure 1c) . Altogether, 11 miRNAs were associated with drug resistance in SGC7901/VCR cells, and miR-508-5p reversed the resistance most efficiently. Meanwhile, the suppression of proliferation by miR-15b/582-5p partially contributed to their suppressive effects on CI.
We performed quantitative reverse transcription PCR (qRT-PCR) to measure the expression levels of the 11 candidate miRNAs in chemo-sensitive and chemo-resistant gastric cancer cells. miR23b, miR-508-5p and miR-582-5p were downregulated in both SGC7901/adriamycin (ADR) and SGC7901/VCR cells, whereas miR15b, miR-16 and miR-27b were repressed only in SGC7901/VCR cells. The expression of the remaining miRNAs was similar in chemo-sensitive and chemo-resistant cells (Figure 1d ).
miR-508-5p regulates the sensitivity of gastric cancer cells to chemotherapeutic agents in vitro In our screening, miR-508-5p was shown to reverse VCR resistance more efficiently than any other miRNA tested. However, the screen did not evaluate whether it regulated resistance to other drugs. To address this question, miR-508-5p mimics (100 nM) were transiently transfected into SGC7901/ADR and SGC7901/VCR cells, and antagomir (100 nM) for miR-508-5p was transfected into SGC7901 cells (Figure 2a ). The overexpression of miR-508-5p markedly sensitized cells to chemotherapy, as indicated by a decrease in the IC 50 values of ADR, VCR, 5-fluorouracil (5FU) and CDDP (Figures 2c and d) . Meanwhile, increased IC 50 values for these four chemotherapeutic agents were observed after miR-508-5p was inhibited by antagomir in SGC7901 cells (Figure 2b ). One major mechanism through which tumours escape from drug-induced damage is by increasing the drug export through P-gp. To determine whether miR-508-5p regulated the function of P-gp, we analysed the intracellular concentration of ADR, a P-gp substrate, in drug-resistant gastric cancer cells transfected with miR-508-5p. These analyses showed that the ADR concentration (red fluorescence) was low in SGC7901/ADR and SGC7901/VCR cells, whereas the restoration of miR-508-5p increased the level of intracellular ADR ( Figures 3A and B) . Meanwhile, knocking down miR-508-5p in SGC7901 cells led to reduced ADR intensity ( Figures  3A and B) . The regulatory role of miR-508-5p was also validated by the increase in apoptosis induced by 5FU (50 mg/ml) in 7901/ADR and 7901/VCR cells upon the restoration of miR-508-5p expression. (Figure 3C ). Conversely, reduced miR-508-5p repression led to a decrease in the apoptosis induced by 5FU (20 mg/ml) in SGC7901 cells ( Figure 3C ). miR-508-5p functions by targeting ABCB1 and ZNRD1 We stably transfected cells with miR-508-5p using lentiviral vectors (Figure 4a ). Using the bioinformatics algorithms TargetScan (http://www.targetscan.org) and miRanda (http://www.microrna.org/microrna/home.do), we selected ABCB1 and ZNRD1 as potential miR-508-5p target genes.
MDR gastric cancer cells with stable miR-508-5p expression showed a significant attenuation of ABCB1 and ZNRD1 expression at both the mRNA and protein levels (Figures 4c, d and f), whereas the inhibition of miR-508-5p led to the opposite changes in ABCB1 and ZNRD1 expression (Figures 4b and e) .
To test whether ABCB1 and ZNRD1 were direct targets of miR-508-5p, luciferase activity assays were performed with luciferase reporters carrying the 3 0 -UTRs of ABCB1 or ZNRD1 in 7901/ADR cells that were stably transfected with the lenti-miR-508-5p vector or control vector. Forced miR-508-5p expression decreased luciferase activity, and this suppression was reversed by the mutation of the target sequences in the 3 0 -UTRs of ABCB1 or ZNRD1 (Figure 4f ). Similar experiments were also repeated in 7901 cells (Supplementary Figure S3) .
We further validated the roles of P-gp and ZNRD1 in drug resistance in gastric cancer. To this end, three pairs of siRNAs for P-gp and ZNRD1 were synthesized, and their inhibitory effects on P-gp and ZNRD1 were confirmed by western blotting (Supplementary Figure S1A) . Remarkably, silencing either P-gp or ZNRD1 sensitized drug-resistant gastric cancer cells to chemotherapeutics by increasing the intracellular concentration of ADR (Supplementary Figure S1C) . Silencing of either P-gp or ZNRD1 decreased the IC 50 values to ADR and VCR and this also markedly increased apoptosis rates when resistant cells were treated with VCR (Supplementary Figures S1B and S1D). However, a different effect was observed between the MDR-associated genes upon treatment with alternative chemotherapeutics. Silencing ZNRD1 decreased the IC 50 values to 5FU and CDDP, whereas silencing P-gp had no such effect (Supplementary Figure  S1B) . Similar to levels of apoptosis, silencing of ZNRD1 sensitized resistant cells to 5FU treatment, whereas silencing of P-gp had no such effect. These data suggested that these proteins may be associated with different drug resistance profiles. To further confirm this activity, we cotransfected SGC7901 cells with an siRNA targeting P-gp and a miR-508-5p antagomir, and found that the effect of the miR-508-5p antagomir was attenuated by P-gp siRNA (Figures 5a and b) . Similar results were found in cells that were cotransfected with an siRNA targeting ZNRD1 and the miR-508-5p antagomir (Figures 5a and b) . We also confirmed that re-expression of P-gp and ZNRD1 could antagonize miR-508-5p-mediated chemo-sensitivity (Supplementary Table S5 ). These results confirmed that miR-508-5p regulated MDR by targeting P-gp and ZNRD1, both of which have important roles in MDR.
Silencing ZNRD1 decreases P-gp expression We observed that silencing ZNRD1 led to an increase in intracellular ADR concentration, and we were particularly interested in determining whether P-gp was involved in this phenomenon. We found that silencing ZNRD1 decreased the expression of P-gp at the mRNA and protein levels, but P-gp knockdown did not affect ZNRD1 (Figures 5c and D) . These findings were consistent with the observed increase in intracellular ADR after ZNRD1 knockdown.
Restoration of miR-508-5p increased the drug sensitivity of drugresistant gastric cancer cells by targeting ABCB1 and ZNRD1 in vivo To investigate whether miR-508-5p regulates the drug sensitivity of gastric cancer cells in vivo, we transplanted SGC7901/VCR cells that had been stably transfected with vector or miR-508-5p into nude mice. The volumes and weights of the miR-508-5p transfected tumours were markedly decreased after chemotherapy, which indicated the reversion of drug resistance by ectopic miR-508-5p expression (Figures 6a-d and Supplementary Figure S6) . At the end of this experiment, the mice were killed and their tumours were isolated. RNA and protein were extracted from the tumour tissues and consecutive slides were prepared. Immunohistochemistry, qRT-PCR and western blotting showed that P-gp and ZNRD1 were decreased at both the mRNA and protein levels due to the increased expression of miR-508-5p, which was consistent with the findings in vitro (Figure 6e ). miR-508-5p expression is inversely correlated with the expression of its target genes and correlates with overall survival in patients with gastric cancer To verify the roles of miR-508-5p in clinical samples, we detected miR-508-5p and its targets by in situ hybridization and immunohistochemistry, respectively. We noted that the expression levels of P-gp and ZNRD1 were decreased in cancerous tissues with stronger expression of miR-508-5p, whereas decreased miR-508-5p tended to increase P-gp and ZNRD1 (Figure 7a , Tables 1  and 2 ). We then analysed the relation between miR-508-5p and the clinicopathological parameters. We found that expression of miR-508-5p did not differ in patients with different factors, including age, gender, differentiation and metastasis status (Supplementary Table S2 ). However, patients in the low miR-508-5p expression group had a significantly poorer prognosis than those in the high miR-508-5p expression group (Figure 7b ).
DISCUSSION
In our functional screen, we used the RT-CES system to collect and analyse drug sensitivity data from cells transfected with individual miRNAs. This method relied on a direct read-out of cell growth rather than a change in mRNA levels or gene copy number, and revealed a different subset of miRNAs than those identified by microarray-or PCR-based techniques. By this, we screened out a subset of miRNAs in MDR of gastric cancer and validated their effects on cell proliferation and chemo-sensitivity (see Supplementary Figures S2 and S4; Supplementary Table S3 ). It was showed that increased miR-508-5p expression sensitized cells to VCR, and subsequent gain-of-function and loss-of-function studies showed that the ectopic expression of miR-508-5p sensitized SGC7901/ADR and SGC7901/VCR cells to ADR, VCR, 5FU and CDDP both in vitro and in vivo. Two downstream targets of miR-508-5p, P-gp and ZNRD1, were identified through bioinformatics analysis. P-gp was the first ATP-binding cassette (ABC) transporter to be characterized. 4 The overexpression of P-gp in cancer cells promoted drug resistance, 6 whereas inhibiting the expression or function of P-gp was shown to reverse drug resistance. 5 These reports defined the classical MDR-associated role of P-gp. Recently, miRNAs have been reported to modulate drug resistance by regulating P-gp. In breast cancer and leukaemia, miR-451 and miR-331-5p were found to regulate P-gp by directly binding to its 3 0 -UTR. [29] [30] In addition to the direct regulation of P-gp by miRNAs, several indirect regulatory mechanisms also exist. According to Zhu et al., 31 P-gp expression is positively regulated by miR-27a in ovarian and cervical cancers, suggesting an indirect regulation of P-gp by miRNAs. In contrast, evidence that miR-27a directly targets the 3 0 -UTR of P-gp was found in leukaemia. 32 Interestingly, miR-27a was also recently associated with the MDR phenotype as a transcriptional regulator in oesophageal squamous cell carcinoma. 33 Taken together, these reports suggest that miR-27a might be a tripartite regulator of P-gp and highlight the multiple potential regulatory roles of miRNAs in P-gp modulation. In our report, we found that miR-508-5p directly targeted sequences within the 3 0 -UTR of P-gp, thus decreasing P-gp expression at the mRNA and protein levels. However, none of the miRNAs mentioned above seemed to regulate P-gp expression and P-gp-associated chemo-resistance (see Supplementary Figure S5 and Supplementary Table S4) . Notably, both unglycosylated (140 kDa) and glycosylated (170 kDa) P-gp were suppressed. Currently, it is unclear whether glycosylation affects the functions of P-gp. Sereš M and colleagues showed that the inhibition of the N-linked glycosylation of P-gp with tunicamycin did not alter the drug efflux function of P-gp. 34 N-linked glycosylation- miRNAs and drug resistance in gastric cancer Y Shang et al deficient P-gp was found to localize to the plasma membrane at a lower level than wild-type P-gp but without an obvious change in function. 35 However, Summerhayes and colleagues 36 also observed increased drug retention in cells exposed to tunicamycin, suggesting a role for glycosylation in establishing the P-gpmediated MDR phenotype. Regardless of these various academic views, miR-508-5p overexpression decreased the expression and glycosylation levels of P-gp and reversed drug resistance by inhibiting the drug transportation through P-gp.
ZNRD1 was identified by our lab as an MDR-associated gene. Previous studies showed that ZNRD1 was upregulated in drugresistant cancer cells, and the knockdown of ZNRD1 significantly reversed MDR in gastric cancer. 12, 37 ZNRD1 was also shown to act as a regulator of BCL-2. [12] [13] We found that miR-508-5p regulated ZNRD1 by targeting its 3 0 -UTR. Meanwhile, P-gp was markedly decreased at the mRNA and protein levels when ZNRD1 was downregulated. This phenomenon explained the increased intracellular ADR concentration and VCR-induced apoptosis observed when ZNRD1 was silenced. Therefore, we proposed that P-gp might be transcriptionally regulated by ZNRD1. In addition, we noticed that ZNRD1 could also regulate drug sensitivity to 5FU and CDDP, whereas P-gp was not associated with 5FU and CDDP resistance. This phenomenon might be owing to the fact that ZNRD1 might transcriptionally regulate a wide range of molecules that could contribute to reversal of 5FU and CDDP resistance. We also noted that P-gp did not affect ZNRD1 because there was no subsequent change in ZNRD1 expression following P-gp inhibition. In fact, according to previous reports, exogenous ZNRD1 expression promoted the transcription of P-gp. 38 In combination, our data revealed the direct and indirect regulation of P-gp by miR-508-5p. First, the overexpression of miR-508-5p decreased P-gp and ZNRD1 expression by directly targeting their 3 0 -UTRs; meanwhile, the inhibition of ZNRD1 by miR-508-5p suppressed P-gp expression. Therefore, the reversion of the P-gp-mediated MDR phenotype in our cell model could be at least partially attributed to a regulatory loop involving miR-508- miRNAs and drug resistance in gastric cancer Y Shang et al 5p, ZNRD1 and P-gp. Meanwhile, silencing P-gp and ZNRD1 reversed the drug resistance induced by miR-508-5p inhibition, and the expression levels of these factors were inversely correlated with miR-508-5p in gastric cancer tissues. These observations indicate that P-gp and ZNRD1 are targets of miR-508-5p.
We noticed that patients with low miR-508-5p expression had a significantly poorer prognosis than those with high miR-508-5p, but miR-508-5p did not correlate with any clinicopathological parameters. This result indicated that miR-508-5p might serve as a MDR-specific miRNA in gastric cancer. Patients in our study all received neoadjuvant chemotherapy, and the sensitivity to chemotherapy of each patient might be directly affected by miR-508-5p expression. Therefore, patients with high miR-508-5p could have better responses to chemotherapy, which in turn leads to the better overall survival. In fact, several miRNAs, including miR-21, miR-let-7a and miR-27a, have been used as predictors of chemoresistance in cancers. [39] [40] [41] In gastric cancer, a link was established between 58 miRNAs and chemo-resistance in patients, suggesting that miRNA signature analysis would be a useful tool for evaluating chemo-resistance in cancers. 42 We found a subset of miRNAs associated with MDR through functional screening, and the on-going analysis of their roles in gastric cancer might be useful in evaluating and managing drug resistance.
The dysregulation of miRNAs in cancer has been widely reported, but its underlying mechanisms remains not fully illustrated. Transcription factors have been indicated to have important roles in regulating miRNAs, and, for instance, a network of miRNAs associated with P53 have been identified. 43 Meanwhile, epigenetic modification, such as methylation, also directly modulated miRNA expression. 44 Through bioinformatics analysis, we found that several transcription factors had potential binding sites in the upstream sequences of miR-508-5p, but further studies should be carried out to demonstrate the regulation of miR-508-5p in gastric cancer.
In conclusion, miR-508-5p is a novel miRNA that regulates MDR in gastric cancer. By targeting ABCB1 and ZNRD1, miR-508-5p overexpression decreases the intracellular concentration of chemotherapeutics and promotes drug-induced apoptosis in MDR gastric cancer cells. In addition, we further validated the function of miR-508-5p in MDR in a xenograft tumour model and clinical gastric cancer specimens, showing that this miRNA also regulated drug resistance in vivo and could be used as the Table 1 . Inverse correlation between miR-508-5p and P-gp
Abbreviation: P-gp, P-glycoprotein. Table 2 . Inverse correlation between miR-508-5p and ZNRD1
Abbreviation: ZNRD1, zinc ribbon domain-containing 1.
miRNAs and drug resistance in gastric cancer Y Shang et al predictor for overall survival. The novel miR-508-5p/P-gp/ZNRD1 regulatory loop characterized here provides new insight into the mechanisms underlying drug resistance, and the restoration of miR-508-5p expression may be a potential therapeutic strategy for the treatment of MDR in gastric cancer in the future.
MATERIALS AND METHODS
Cell culture
The human gastric cancer cell line SGC7901 and its MDR variants SGC7901/VCR and SGC7901/ADR (established and maintained in our laboratory) were maintained in our laboratory in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% foetal bovine serum (Gibco, Carlsbad, CA, USA), 100 U/ml penicillin sodium and 100 mg/ml streptomycin sulphate at 37 1C in a humidified air atmosphere containing 5% CO 2 . To maintain the MDR phenotype, VCR and ADR at final concentrations of 1 mg/ml and 0.5 mg/ml, were added to the culture media of SGC7901/VCR and SGC7901/ADR cells, respectively.
The functional screening of miRNAs Approximately 5 Â 10 3 SGC7901/VCR cells were plated into 96-well plates, and 100 nM miRNA mimics were transfected into cells with siPORT NeoFX (Invitrogen, Carlsbad, CA, USA). After transfection, the cells were moved to 96-well E-plates, incubated for 24 h, and treated with 2 mg/ml VCR. The CI value, which represents the number and growth state of attached cells, was measured automatically by the RT-CES system once per hour for 96 h. [45] [46] At the end of the screening, a Z-score was automatically calculated. miRNAs with a Z-score lower than À 3.0 were considered MDR regulatory miRNAs in SGC7901/VCR. 45 
RNA extraction and real-time qRT-PCR
Total RNA was extracted from cells or tissues using TRIzol reagent (Invitrogen). To detect the expression of miR-508-5p, stem-loop reverse transcription PCR (RT-PCR) was performed using an All-in-One miRNA qRT-PCR Detection Kit (GeneCopoeia, Rockville, MD, USA) according to the manufacturer's instructions. Primers for miR-508-5p and U6 were purchased from GeneCopoeia. qRT-PCR was performed to detect ABCB1 and ZNRD1 mRNA using the SYBR Green PCR Kit (Takara Bio Inc., Otsu, Japan). ABCB1 and ZNRD1 mRNA expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels. Primer sequences were showed in Supplementary Table S1 .
Oligonucleotide construction and lentivirus production Mimics, antagomir and negative control oligonucleotides for hsa-miR-508-5p were obtained from RiboBio Co. Ltd (Guangzhou, Guangdong, China). siRNAs targeting ABCB1 and ZNRD1 were purchased from RiboBio Co. Ltd. Target cells were transfected with the oligonucleotides using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Stable transfectants overexpressing miR-508-5p were generated by lentiviral transduction using a pGCsil-GFP vector (GeneChem Co., Ltd, Shanghai, China). As a control, we also generated a lentiviral vector (LV) that expressed green fluorescent protein (LV-GFP) alone.
In vitro drug sensitivity assay
A miR-508-5p antagomir was transfected into SGC7901 cells, and miR-508-5p mimics were transfected into SGC7901/ADR and SGC/7901VCR cells. The drug sensitivity assay was performed as described previously. 13 Briefly, 5 Â 10 3 cell were seeded into 96-well plate and medium containing drugs was added into each well. After incubated for 48 h, 3-(4,5-di-methyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT, Sigma, St Louis, MO, USA) assay was performed. The inhibition rates and IC 50 values were then calculated.
Intracellular ADR concentration analysis
For the ADR fluorescence analysis, cells were stained with 10 mM 3,3 0 -dioctadecyloxacarbocyanine perchlorate (DIO) (Beyotime Biotechnology, Shanghai, China) for 20 min and then incubated in medium containing ADR (10 mg/ml, Sigma) for 2 h. The cells were then washed with fresh medium and placed into a cellomics instrument (Thermo Fisher, Waltham, MA, USA). The ADR fluorescence was then read and imaged.
Apoptosis assay
Cell apoptosis was evaluated using an Annexin-V-FITC apoptosis detection kit (BD, Franklin Lakes, NJ, USA) as previously described. 13 Luciferase assay Plasmids containing wild-type Luc-ABCB1, mutant Luc-ABCB1, wild-type Luc-ZNRD1 or mutant Luc-ZNRD1 3 0 -UTR were synthesized (GeneCopoeia). The luciferase assay was performed as previously described. 20 Western blotting Cells or tissues were solubilized in RIPA (Beyotime, China) containing protease inhibitors (Roche, Switzerland), and western blotting was performed as previously described. 21 Primary antibodies against P-gp, ZNRD1 and b-actin (Sigma) were used.
Tissue microarrays
Gastric cancer tissue microarrays (shBiochip, Shanghai, China) included 111 cases of gastric malignant tissues with detailed clinicopathological and follow-up information. For each case, three cylinders of cancerous gastric tissues were included. All patients included in the microarrays received neoadjuvant chemotherapy.
Immunohistochemistry and in situ hybridization
The immunohistochemical staining of P-gp and ZNRD1 was performed as previously described. 19 Target protein expression was evaluated according to the ratio of positive cells per specimen, and staining intensity was determined according to a histological scoring method. The proportion of positive cells in each specimen was evaluated quantitatively and scored 0 for staining of 0%, 1 for 0.01-25%, 2 for 25.01-50%, 3 for 50.01-75% and 4 for X75% of the cells examined. Intensity was graded as follows: 0, no signal; 1, weak; 2, moderate; and 3, strong staining. The histological score of P-gp expression for each section was computed by the following formula: histological score ¼ ratio score Â intensity score. A total score of 0-12 was calculated and graded as negative ( À , score: 0), weak ( þ , score: 1-4), moderate ( þ þ , score: 5-8) or strong ( þ þ þ , score: 9-12).
In situ hybridization was performed using a miR-508-5p probe from Exiqon (miRCURY LNA detection probe 5 0 -digoxigenin-labelled). The probe was detected using digoxigenin antibody (Abcam, Cambridge, UK), LSAB2 System-HRP (Dako Denmark A/S, Glostrup, Denmark) and liquid DAB þ Substrate Chromogen System (Dako) according to the manufacturer's instructions. The scoring of hybridization was the same as mentioned. Scoring with ' À ' and ' þ ' was regarded as lower miR-508-5p expression, whereas ' þ þ ' and ' þ þ þ ' represented higher expression of miR-508-5p.
The results of immunostaining and hybridization were independently scored by two pathologists (Zengshan Li and Zhe Wang) in a blind manner.
In vivo drug sensitivity assay Approximately 1.0 Â 10 7 SGC7901/VCR cells stably transfected with lentimiR-508-5p or control vector were subcutaneously injected into both flanks of nude mice. Two weeks later, the mice were intraperitoneally injected with PBS containing ADR, VCR, 5FU or CDDP once per week. Tumour volume was measured with a Vernier calliper on days 7, 14, 21 and 28, and calculated as volume ¼ length Â width. 2 The mice were humanely killed on day 28, and the tumours were weighed and photographed. Immunohistochemistry, western blotting and qRT-PCR were performed for Ki67, P-gp and ZNRD1.
Statistical analysis
The data are presented as the mean ± s.e. of the mean. Student's t-test (two-tailed) or a one-way analysis of variance was employed to analyse the in vitro and in vivo data. w 2 -test was used to analyse the relationship between miR-508-5p expression and clinicopathological factors. Spearman's correlation test was used to analyse miR-508-5p and its targets.
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